dehydroepiandrosterone sulfate has been researched along with Fibroid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kettel, LM; Morales, AJ; Murphy, AA; Roberts, VJ; Yen, SS | 1 |
| Andreyko, JL; Blumenfeld, Z; Hricak, H; Jaffe, RB; Marshall, LA; Monroe, SE | 1 |
2 other study(ies) available for dehydroepiandrosterone sulfate and Fibroid
| Article | Year |
|---|---|
Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Topics: Adolescent; Adult; Androstenedione; Bone Density; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Follicle Stimulating Hormone; Humans; Hysterectomy; Immunohistochemistry; Leiomyoma; Luteinizing Hormone; Middle Aged; Mifepristone; Myometrium; Progesterone; Receptors, Estradiol; Receptors, Progesterone; Testosterone; Uterine Neoplasms | 1993 |
Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Drug Evaluation; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Luteinizing Hormone; Magnetic Resonance Imaging; Nafarelin; Testosterone; Time Factors; Uterine Neoplasms | 1988 |